PCVX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
302.8M
-12.5%
345.9M
+26.1%
274.3M
+13.2%
242.4M
+7.1%
226.2M
R&D
267.9M
-14.4%
312.8M
+29.2%
242.1M
+15.3%
209.9M
+8.1%
194.2M
SG&A
34.9M
+5.6%
33.1M
+2.6%
32.2M
-0.7%
32.4M
+1.3%
32.0M
Operating Income
-302777000
+12.5%
-345850000
-26.1%
-274283000
-13.2%
-242380000
-7.1%
-226219000
EBITDA
-299775000
+12.6%
-342903000
-32.7%
-258322000
-7.9%
-239316000
-7.2%
-223340000
Net Income
-284302000
+11.3%
-320622000
-30.1%
-246507000
-15.8%
-212830000
-27.8%
-166573000
EPS (Basic)
$-1.97
+14.3%
$-2.30
-27.1%
$-1.81
-16.0%
$-1.56
-27.9%
$-1.22
EPS (Diluted)
$-1.97
+14.3%
$-2.30
-27.1%
$-1.81
-16.0%
$-1.56
-27.9%
$-1.22
Shares (Diluted)
144.5M
+3.6%
139.5M
+2.3%
136.4M
+0.2%
136.2M
+0.1%
136.0M
Vaxcyte (PCVX) โ€” Financials